Leerink Partners Remains Bullish on Cerner (CERN) Following Weak 3Q Report
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil tops $100, yields hit 2023 high; Apple down before Ternus' first launch event as CEO
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Baird Downgrades Cerner (CERN) to Neutral
November 2, 2016 6:41 AM EDTBaird downgraded Cerner (NASDAQ: CERN) from Outperform to Neutral with a price target of $58.00 (from $68.00).
For an analyst ratings summary and ratings history on Cerner click here. For more ratings news on Cerner click here.
Shares of Cerner closed at $57.34 yesterday.
... MoreAfter-Hours Stock Movers 11/01: (PTN) (AVXS) (EA) Higher; (ADPT) (ZAGG) (DXCM) Lower (more...)
November 1, 2016 6:25 PM EDTToday's After-Hours Movers
Adeptus Health (NYSE: ADPT) 48% LOWER; reported Q3 EPS of $0.06, $0.50 worse than the analyst estimate of $0.56. Revenue for the quarter came in at $85.4 million versus the consensus estimate of $89.99 million.
Palatin Technologies, Inc. (NYSE: PTN) 46.9% HIGHER; announced positive, statistically significant top-line results from the Reconnect Studies, its Phase 3 clinical trial program of lead drug candidate bremelanotide. The Reconnect Studies, investigating bremelanotide as an on-demand treatment for premenopausal women diagnosed with hypoactive sexual desire disorder ("HSDD"), met the... More
Cerner (CERN) Misses Q3 EPS by 1c, Offers Q4 & FY17 Guidance
November 1, 2016 4:09 PM EDTCerner (NASDAQ: CERN) reported Q3 EPS of $0.59, $0.01 worse than the analyst estimate of $0.60. Revenue for the quarter came in at $1.19 billion versus the consensus estimate of $1.24 billion.
GUIDANCE:
Cerner sees Q4 2016 EPS of $0.60-$0.62, versus the consensus of $0.65. Cerner sees Q4... More
Trading Radar for 11/1: Kellogg (K), Electronic Arts (EA), Mosaic (MOS), Herbalife (HLF), Western Union (WU) Report
October 31, 2016 2:54 PM EDTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Earnings:
Adeptus Health (NYSE: ADPT) - consensus EPS $0.56
Aircastle Limited (NYSE: AYR) - consensus EPS $0.43
Allot Communications (Nasdaq: ALLT) - consensus EPS $0.02
Ameresco (NYSE: AMRC) - consensus EPS $0.09
Ametek (NYSE: AME) - consensus EPS $0.55
Ampco-Pittsburgh (NYSE: AP) - no Street consensus... More
